Press Releases GeNeuro SA

Equities

GNRO

CH0308403085

Real-time Euronext Paris Other stock markets 05:15:53 07/05/2024 pm IST			5-day change	1st Jan Change
1.465 ^EUR	+0.34%		+0.34%	+34.40%

20/03	Geneuro SA Announces Appointments of Board of Directors	CI
02/02	GeNeuro: share price falls after private placement	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GeNeuro Publishes its 2024 Universal Registration Document	02/05	BU
GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update	30/04	BU
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting	20/03	BU
GeNeuro - Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications	12/12	AQ
GeNeuro : Investor Presentation October 2023	20/23/20	PU
GeNeuro : Half yearly financial reports and audit reports/limited reviews / Half yearly financial report	06/23/06	PU
GeNeuro Reports 2023 Half-Year Results and Provides Corporate Update	03/23/03	AQ
GeNeuro - New study published in PNAS further substantiates the neuropathogenic role of the HERV-W protein in MS	28/23/28	AQ
GeNeuro, financial information for the second quarter 2023	26/23/26	AQ
GeNeuro : Result of votes at Annual General Meeting of Shareholders of 14 June 2023	22/23/22	PU
GeNeuro Announces Approval of all Resolutions Proposed at 2023 Annual General Meeting	16/23/16	AQ
GeNeuro : Inside Information / Other news releases	03/23/03	PU
GeNeuro : 2022 Universal Registration Document	01/23/01	PU
GeNeuro : 2022 Universal Registration Document	29/23/29	PU
GeNeuro : Document Universel d'Enregistrement 2022 (en anglais)	28/23/28	PU
GeNeuro, financial information for the first quarter 2023	14/23/14	AQ
GeNeuro Reports 2022 Full-Year Results and Provides Corporate Update	06/23/06	AQ
The EIB and GeNeuro sign a EUR 25 million credit line backed by InvestEU to support clinical developments against long-COVID	08/23/08	AQ
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab	17/22/17	AQ
The Karolinska Institutet's Academic Specialist Center to Present Results of GeNeuro's ProTEct-MS Phase 2 Study of Temelimab at ECTRIMS 2022	25/22/25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GeNeuro SA

Equities

GNRO

CH0308403085

Press Releases

Filters